
News|Articles|April 30, 2025
Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.
Advertisement
Advertisement
Vaccines are a major topic of interest in the world of cancer care, offering the promise of an effective treatment option in traditionally hard-to-manage tumor types that can potentially be personalized for individual patients. In order to further elucidate the current role of vaccines in the therapeutic paradigm of multiple tumor types and learn more about promising vaccines in development, OncLive® interviewed several investigators to gain their perspective on these exciting agents.
Related to this article

The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.

Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.

A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.

Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Advertisement
Advertisement

